Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 9

The DOI matches its Crossref record.

Bioavailability of Antibiotics and Their Toxicity

Ullah, Izhar, Ali, Essa, Fakhar-ud-Din·2020·Emerging Contaminants and Associated Treatment Technologies

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/978-3-030-40422-2_10

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 201

  1. Abramowicz M (2003) Hypoglycemia and hyperglycemia with fluoroquinolones. Med Lett Drugs Ther 45:64–64
  2. Abu-Basha E, Gehring R, Hantash T, Al-Shunnaq A, Idkaidek N (2009) Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). J Vet Pharmacol Ther 32:258–263 · doi:10.1111/j.1365-2885.2008.01036.x
  3. Actor P, Chow AW, Dutko FJ, McKinlay MA (2000) Chemotherapeutics. Ullmann’s Encyclopedia of Industrial Chemistry · DOI
  4. Agarwal A, Kharb V, Saharan VA (2014) Process optimisation, characterisation and evaluation of resveratrol-phospholipid complexes using box-Behnken statistical design. Int Curr Pharmaceut J 3:301–308 · doi:10.3329/icpj.v3i7.19079
  5. Agwuh KN, MacGowan A (2006) Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58:256–265 · DOI · Paper page
  6. Albarellos GA, Montoya L, Passini SM, Lupi MP, Lorenzini PM, Landoni MF (2016) Pharmacokinetics of meropenem after intravenous, intramuscular and subcutaneous administration to cats. J Feline Med Surg 18:976–980 · doi:10.1177/1098612x15604655
  7. Aldred KJ, Kerns RJ, Osheroff N (2014) Mechanism of quinolone action and resistance. Biochemistry 53:1565–1574 · DOI · Paper page
  8. Allam AN, El Gamal S, Naggar V (2011) Bioavailability: a pharmaceutical review. Int J Novel Drug Deliv Tech 1:77–93
  9. Ambrose PJ (1984) Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet 9:222–238 · DOI
  10. Ambrose CT, Coons AH (1963) Studies on antibody production: VIII The inhibitory effect of chloramphenicol on the synthesis of antibody in tissue culture. J Exp Med 117:1075–1088 · DOI · Paper page
  11. Appel GB, Neu HC (1977) The nephrotoxicity of antimicrobial agents. N Engl J Med 296:663–670 · doi:10.1056/nejm197703242961205
  12. Baert K, De Baere S, Croubels S, De Backer P (2003) Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens. Vet Res Commun 27:301–309 · doi:10.1023/a:1024084108803
  13. Bahal N, Nahata MC (1992) The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 26:46–55 · doi:10.1177/106002809202600112
  14. Balbi H (2004) Chloramphenicol: a review. Pediatr Rev 25:284–288 · DOI
  15. Ball P, Mandell L, Patou G, Dankner W, Tillotson G (2004) A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 23:421–429 · doi:10.1016/j.ijantimicag.2004.02.014
  16. Bargoni A, Cavalli R, Zara GP, Fundarò A, Caputo O, Gasco MR (2001) Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II—tissue distribution. Pharmacol Res 43:497–502 · DOI
  17. Barrons RW, Murray KM, Richey RM (1992) Populations at risk for penicillin-induced seizures. Ann Pharmacother 26:26–29 · doi:10.1177/106002809202600106
  18. Barza M, Weinstein L (1976) Pharmacokinetics of the penicillins in man. Clin Pharmacokinet 1:297–308 · DOI
  19. Barza M, Furie B, Brown AE, Furie BC (1986) Defects in vitamin K-dependent carboxylation associated with moxalactam treatment. J Infect Dis 153:1166–1169 · doi:10.1093/infdis/153.6.1166
  20. Bennett JE, Dolin R, Blaser MJ (2014) Principles and practice of infectious diseases, 1. Elsevier health sciences
  21. Bethell H (1977) Photo-onycholysis caused by demethylchlortetracycline. Br Med J 2:96 · doi:10.1136/bmj.2.6079.96
  22. Beveridge TJ (1999) Structures of gram-negative cell walls and their derived membrane vesicles. J Bacteriol 181:4725–4733 · DOI · Paper page
  23. Bhandari R, Kaur IP (2013) Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm 441:202–212 · DOI
  24. Bissuel F, Cotte L, de Montclos M, Rabodonirina M, Trepo C (1994) Absence of systemic absorption of oral paromomycin during long-term, high-dose treatment for cryptosporidiosis in AIDS. J Infect Dis 170:749–750 · doi:10.1093/infdis/170.3.749
  25. Blumberg HM, Burman WJ, Chaisson RE, Daley CL (2003) American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167:603 · DOI · Paper page
  26. Blumenthal KG, Patil SU, Long AA (2012) The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, allergy and asthma proceedings. OceanSide Publications, Inc, East Providence, pp 165–171
  27. Bo G (2000) Giuseppe Brotzu and the discovery of cephalosporins. Clin Microbiol Infect 6:6–8 · doi:10.1111/j.1469-0691.2000.tb02032.x
  28. Bosso JA (2005) The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy 25:55S–62S · DOI
  29. Breen KJ, Bryant RE, Levinson JD, Schenker S (1972) Neomycin absorption in man: studies of oral and enema administration and effect of intestinal ulceration. Ann Intern Med 76:211–218 · doi:10.7326/0003-4819-76-2-211
  30. Brunner M, Pernerstorfer T, Mayer BX, Eichler HG, Müller M (2000) Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 28:1754–1759 · doi:10.1097/00003246-200006000-00009
  31. Buchholtz K, Larsen CT, Hassager C, Bruun NE (2009) Severity of gentamicin’s nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin Infect Dis 48:65–71 · DOI
  32. Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, Das K (1993) Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 119:576–583 · DOI
  33. Chatterjee V, Buchanan D, Friedmann A, Green M (1986) Ocular toxicity following ethambutol in standard dosage. Br J Dis Chest 80:288–291 · doi:10.1016/0007-0971(86)90066-5
  34. Chirumamilla SK, Padasala UD, Aravally H, Vuppalapati L, Cherukuri S (2017) Solubility and dissolution enhancement of Meropenem by Nano suspension approach. J Young Pharm 9(3):429–435 · DOI
  35. Chiu AM, Chuenkongkaew WL, Cornblath WT, Trobe JD, Digre KB, Dotan SA, Musson KH, Eggenberger ER (1998) Minocycline treatment and pseudotumor cerebri syndrome. Am J Ophthalmol 126:116–121 · DOI
  36. Chopra I (2011) Tetracyclines, antibiotic and chemotherapy (ninth edition). Elsevier, Amsterdam, pp 344–355
  37. Chung M, Schrogie JJ, Symchowicz S (1981) Pharmacokinetic study of sisomicin in humans. J Pharmacokinet Biopharm 9:535–551 · doi:10.1007/bf01061025
  38. Cohen ML (2000) Changing patterns of infectious disease. Nature 406:762 · DOI · Paper page
  39. Cohlan SQ (1963) Teratogenic agents and congenital malformations. J Pediatr 63:650–659 · DOI
  40. Cooper WO, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA (2002) Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 156:647–650 · DOI
  41. Craig WA (1997) The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis 24:S266–S275 · DOI · Paper page
  42. Craven GR, Gavin R, Fanning T (1969) The transfer RNA binding site of the 30 S ribosome and the site of tetracycline inhibition, cold Spring Harbor symposia on quantitative biology. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 129–137
  43. Dasgupta A (2012) Therapeutic drug monitoring: newer drugs and biomarkers. Academic Press, New York · DOI
  44. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346:747–750 · DOI · Paper page
  45. Demers P, Fraser D, Goldbloom R, Haworth J, LaRochelle J, MacLean R, Murray T (1968) Effects of tetracyclines on skeletal growth and dentition. A report by the nutrition Committee of the Canadian Paediatric Society. Can Med Assoc J 99:849
  46. Denamur S, Van Bambeke F, Mingeot-Leclercq M-P, Tulkens PM (2008) Apoptosis induced by aminoglycosides in LLC-PK1 cells: comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation. Antimicrob Agents Chemother 52:2236–2238 · doi:10.1128/aac.01680-07
  47. Domagala JM (1994) Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 33:685–706 · DOI · Paper page
  48. Dong Z, Xie S, Zhu L, Wang Y, Wang X, Zhou W (2011) Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery. Drug Deliv 18:441–450 · DOI
  49. Driessen O, Sorgedrager N, Michel M, Kerrebijn K, Hermans J (1978) Pharmacokinetic aspects of therapy with ampicillin and kanamycin in new-born infants. Eur J Clin Pharmacol 13:449–457 · doi:10.1007/bf00566325
  50. Duggar BM (1948) Aureomycin: a product of the continuing search for new antibiotics. Ann N Y Acad Sci 51:177–181 · DOI · Paper page
  51. Eckman M, Johnson T, Riess R (1975) Partial deafness after erythromycin. N Engl J Med 292:649
  52. Edelstein PH (2004) Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes. Clin Infect Dis 38:S322–S327 · DOI
  53. Ehrlich J, Bartz QR, Smith RM, Joslyn DA (1947) Chloromyeetin, a new antibiotic from a soil actinomycete. Science (Washington) 106(2757):417 · DOI · Paper page
  54. El-Kattan AF, Lee MS (2017) Oral bioavailability assessment: basics and strategies for drug discovery and development. Wiley, Hoboken · doi:10.1002/9781118916926
  55. El-Komy A (1995) Disposition kinetics and bioavailability of piperacillin and cephapirin in mares. Dtsch Tierarztl Wochenschr 102:244–248
  56. Ellsworth A, Christensen D, Volpone-McMahon M (1990) Prospective comparison of patient tolerance to enteric-coated vs nonenteric-coated erythromycin. J Fam Pract 31:265–270
  57. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A (2012) Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68:1243–1255 · DOI · Paper page
  58. Ensign LM, Cone R, Hanes J (2012) Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 64:557–570 · DOI · Paper page
  59. Eyster H (1943) Mechanism of sulfanilamide action and its interaction with p-amino benzoic acid. J Cell Comp Physiol 21:191–198 · doi:10.1002/jcp.1030210211
  60. Fabre J, Rudhardt M, Blanchard P, Regamey C (1976) Persistence of sisomicin and gentamicin in renal cortex and medulla compared with other organs and serum of rats. Kidney Int 10:444–449 · doi:10.1038/ki.1976.131
  61. Fainstein V, Bodey G, McCredie K, Keating M, Estey E, Bolivar R, Elting L (1983) Coagulation abnormalities induced by β-lactam antibiotics in cancer patients. J Infect Dis 148:745–750 · doi:10.1093/infdis/148.4.745
  62. Fanning WL, Gump DW, Sofferman RA (1977) Side effects of minocycline: a double-blind study. Antimicrob Agents Chemother 11:712–717 · DOI
  63. Faulkner R, Fernandez P, Lawrence G, Sia L, Falkowski A, Weiss A, Yacobi A, Silber B (1988) Absolute bioavailability of cefixime in man. J Clin Pharmacol 28:700–706 · doi:10.1002/j.1552-4604.1988.tb03203.x
  64. Finch R, Schürmann D, Collins O, Kubin R, McGivern J, Bobbaers H, Izquierdo J, Nikolaides P, Ogundare F, Raz R (2002) Randomized controlled trial of sequential intravenous (iv) and oral moxifloxacin compared with sequential iv and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 46:1746–1754 · DOI · Paper page
  65. Florek J, Caillard R, Kleitz F (2017) Evaluation of mesoporous silica nanoparticles for oral drug delivery–current status and perspective of MSNs drug carriers. Nanoscale 9:15252–15277 · DOI · Paper page
  66. Foster TS, Raehl CL, Wilson HD (1980) Disulfiram-like reaction associated with a parenteral cephalosporin. Am J Health Syst Pharm 37:858–859 · doi:10.1093/ajhp/37.6.858
  67. François B, Russell RJ, Murray JB, Aboul-ela F, Masquida B, Vicens Q, Westhof E (2005) Crystal structures of complexes between aminoglycosides and decoding a site oligonucleotides: role of the number of rings and positive charges in the specific binding leading to miscoding. Nucleic Acids Res 33:5677–5690 · DOI · Paper page
  68. Fraser TG, Stosor V, Wang Q, Allen A, Zembower TR (2005) Vancomycin and home health care. Emerg Infect Dis 11:1558 · DOI
  69. Fung AT, Hudson B, Billson FA (2011) Chloramphenicol–not so innocuous: a case of optic neuritis. BMJ Case Rep 2011:bcr1020103434
  70. Fuoco D (2012) Classification framework and chemical biology of tetracycline-structure-based drugs. Antibiotics 1:1 · DOI
  71. García-Carbonell MC, Granero L, Torres-Molina F, Aristorena J-C, Chesa-Jimenez J, Pla-Delfina J, Peris-Ribera J (1993) Nonlinear pharmacokinetics of cefadroxil in the rat. Drug Metab Dispos 21:215–217
  72. Geeaci J, Heilman F, Nichols D, Wellman W (1958) Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis. Preliminary report, proceedings of staff meetings of the Mayo Clinic, pp 172–181
  73. Gips M, Soback S (1996) Norfloxacin nicotinate pharmacokinetics in unwearied and weaned calves. J Vet Pharmacol Ther 19:130–134 · doi:10.1111/j.1365-2885.1996.tb00025.x
  74. Green C, Cameron H, Julian G (1975) Recovery of polysome function of T4-infected Escherichia coli after brief treatment with chloramphenicol and rifampin. Antimicrob Agents Chemother 7:549–554 · doi:10.1128/aac.7.5.549
  75. Griffith R, Black H (1970) Cephalexin. Med Clin North Am 54:1229–1244 · doi:10.1016/s0025-7125(16)32589-5
  76. Hata H, Saeki S, Kimura T, Sugahara Y, Kuroda K (1999) Adsorption of taxol into ordered mesoporous silicas with various pore diameters. Chem Mater 11:1110–1119 · DOI
  77. Hebert AA, Sigman ES, Levy ML (1991) Serum sickness—like reactions from cefaclor in children. J Am Acad Dermatol 25:805–808 · doi:10.1016/s0190-9622(08)80973-5
  78. Hemaiswarya S, Kruthiventi AK, Doble M (2008) Synergism between natural products and antibiotics against infectious diseases. Phytomedicine 15:639–652 · DOI · Paper page
  79. Hens B, Brouwers J, Anneveld B, Corsetti M, Symillides M, Vertzoni M, Reppas C, Turner DB, Augustijns P (2014) Gastrointestinal transfer: in vivo evaluation and implementation in in vitro and in silico predictive tools. Eur J Pharm Sci 63:233–242 · DOI
  80. Hey H, Jørgensen F, Sørensen K, Hasselbalch H, Wamberg T (1982) Oesophageal transit of six commonly used tablets and capsules. Br Med J (Clin Res Ed) 285:1717–1719 · doi:10.1136/bmj.285.6356.1717
  81. Hinshaw H, Feldman W (1945) Streptomycin in treatment of clinical tuberculosis: a preliminary report, proceedings of staff meetings of the Mayo Clinic, pp 313–318
  82. Hopefl AW (1985) Aztreonam—an overview. Drug Intell Clin Pharm 19:171–175 · doi:10.1177/106002808501900301
  83. Hou C-D, Wang J-X, Le Y, Zou H-K, Zhao H (2012) Preparation of azithromycin nanosuspensions by reactive precipitation method. Drug Dev Ind Pharm 38:848–854 · DOI
  84. Humbert G, Leroy A, Fillastre J, Oksenhendler G (1978) Pharmacokinetics of netilmicin in the presence of normal or impaired renal function. Antimicrob Agents Chemother 14:40–44 · doi:10.1128/aac.14.1.40
  85. Humbert G, Spyker DA, Fillastre J, Leroy A (1979) Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function. Antimicrob Agents Chemother 15:28–33 · doi:10.1128/aac.15.1.28
  86. Ingalls CS, Freimer EH (1992) Detection of antibiotic-induced platelet dysfunction in whole blood using flow cytometry. J Antimicrob Chemother 29:313–321 · doi:10.1093/jac/29.3.313
  87. Inman W, Rawson N (1983) Erythromycin estolate and jaundice. Br Med J (Clin Res Ed) 286:1954–1955 · doi:10.1136/bmj.286.6382.1954
  88. Iseman MD, Cohn DL, Sbarbaro JA (1993) Directly observed treatment of tuberculosis—we can’t afford not to try it. N Engl J Med 328:576–578 · DOI · Paper page
  89. Josefsson K, Bergan T (1982) Pharmacokinetics of phenoxymethylpenicillin in volunteers. Chemotherapy 28:241–246 · doi:10.1159/000238084
  90. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Müller M (2001) Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 29:385–391 · DOI · Paper page
  91. Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M (1972) Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man. J Pharm Sci 61:773–778 · DOI
  92. Karmody CS, Weinstein L (1977) Reversible sensorineural hearing loss with intravenous erythromycin lactobionate. Ann Otol Rhinol Laryngol 86:9–11 · doi:10.1177/000348947708600103
  93. Katapadi K, Kostandy G, Katapadi M, Hussain K, Schifter D (1997) A review of erythromycin-induced malignant tachyarrhythmia—torsade de pointes: a case report. Angiology 48:821–826 · DOI
  94. Keating GM, Perry CM (2005) Ertapenem. Drugs 65:2151–2178 · DOI
  95. Kelkar PS, Li JT-C (2001) Cephalosporin allergy. N Engl J Med 345:804–809 · DOI · Paper page
  96. Kerr RO, Cardamone J, Dalmasso AP, Kaplan ME (1972) Two mechanisms of erythrocyte destruction in penicillin-induced hemolytic anemia. N Engl J Med 287:1322–1325 · doi:10.1056/nejm197212282872604
  97. Kip AE, Schellens JH, Beijnen JH, Dorlo TP (2018) Clinical pharmacokinetics of systemically administered antileishmanial drugs. Clin Pharmacokinet 57:151–176 · DOI
  98. Klein JO, Finland M (1963) Nafcillin: antibacterial action in vitro and absorption and excretion in Normal young men. Am J Med Sci 246:10–26 · doi:10.1097/00000441-196307000-00002
  99. Kolkman W, Groeneveld J, Baur H, Verschuur H (2002) Ototoxicity induced by clarithromycin. Ned Tijdschr Geneeskd 146:1743–1745
  100. Kuhlmann J, Dalhoff A, Zeiler H-J (2012) Quinolone antibacterials, vol 127. Springer Science & Business Media, New York
  101. Leclercq R, Courvalin P (2002) Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 46:2727–2734 · DOI · Paper page
  102. Libke RD, Clarke JT, Ralph ED, Luthy RP, Kirby WM (1975) Ticarcillin vs carbenicillin: clinical pharmacokinetics. Clin Pharmacol Therapeut 17:441–446 · doi:10.1002/cpt1975174441
  103. Lin C-H, Chen C-H, Lin Z-C, Fang J-Y (2017) Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J Food Drug Anal 25:219–234 · DOI · Paper page
  104. Lipsky BA, Baker CA, McDonald LL, Suzuki NT (1999) Improving the appropriateness of vancomycin use by sequential interventions. Am J Infect Control 27:84–90 · doi:10.1016/s0196-6553(99)70086-6
  105. Lochhead J, Elston J (2003) Doxycycline induced intracranial hypertension. BMJ 326:641–642 · doi:10.1136/bmj.326.7390.641
  106. Lode H, Elvers A, Koeppe P, Borner K (1984) Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother 25:105–108 · doi:10.1128/aac.25.1.105
  107. Longo G, Valenti C, Gandini G, Ferrara L, Bertesi M, Emilia G (1997) Azithromycin-induced intrahepatic cholestasis. Am J Med 102:217
  108. Loos U, Musch E, Jensen J, Mikus G, Schwabe H, Eichelbaum M (1985) Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 63:1205–1211 · DOI
  109. Low CL, Gopalakrishna K, Lye WC (2000) Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 11:1117–1121 · doi:10.1681/asn.v1161117
  110. Lynch SR, Puglisi JD (2001) Structural origins of aminoglycoside specificity for prokaryotic ribosomes1. J Mol Biol 306:1037–1058 · DOI
  111. MacGregor RR, Graziani AL (1997) Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis 24:457–467 · DOI
  112. Madison JF (1963) Tetracycline pigmentation of teeth. Arch Dermatol 88:58–59 · doi:10.1001/archderm.1963.01590190064008
  113. Manyan DR, Arimura GK, Yunis AA (1972) Chloramphenicol-induced erythroid suppression and bone marrow ferrochelatase activity in dogs. J Lab Clin Med 79:137–144
  114. Maraqa NF, Gomez MM, Rathore MH, Alvarez AM (2002) Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Infect Dis 34:50–54 · DOI
  115. Marshall WF, Blair JE (1999) The cephalosporins, Mayo Clinic proceedings. Elsevier, Amsterdam, pp 187–195
  116. Martinez MN, Amidon GL (2002) A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 42:620–643 · DOI · Paper page
  117. Mccaffrey RP, Halsted CH, Wahab MFA, Robertson RP (1971) Chloramphenicol-induced hemolysis in Caucasian glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 74:722–726 · DOI
  118. Meyers B, Hirschman S, Strougo L, Srulevitch E (1980) Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics. Antimicrob Agents Chemother 17:608–611 · DOI
  119. Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL (2011) Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy 31:408–423 · DOI
  120. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD (1976) Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84:181–192 · DOI · Paper page
  121. Mizuno N, Nishikata M, Morita E, Miyake K (1986) Gastrointestinal absorption of sulfaguanidine in neonatal and adult rats. Aust J Pharm 9:787–792
  122. Moffitt JM, Cooley RO, Olsen NH, Hefferren JJ (1974) Prediction of tetracycline-induced tooth discoloration. J Am Dent Assoc 88:547–552 · doi:10.14219/jada.archive.1974.0150
  123. Mori H, Takahashi K, Mizutani T (2007) Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev 39:647–657 · DOI
  124. Musser J, Anderson K (2001) Bioavailability and disposition of sodium and procaine penicillin G (benzylpenicillin) administered orally with milk to calves. J Vet Pharmacol Ther 24:161–169 · doi:10.1046/j.1365-2885.2001.00325.x
  125. Myers AL, Gaedigk A, Dai H, James LP, Jones BL, Neville KA (2012) Defining risk factors for red man syndrome in children and adults. Pediatr Infect Dis J 31:464 · DOI
  126. Namba S, Igari T, Nishiyama K, Hashimoto K, Takemura T, Kimura K (1991) A case of pyrazinamide-associated myoglobinuric renal failure. Jpn J Med 30:468–472 · doi:10.2169/internalmedicine1962.30.468
  127. Nathwani D, Wood MJ (1993) Penicillins. Drugs 45:866–894 · DOI
  128. Nauta E, Mattie H (1975) Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis. Br J Clin Pharmacol 2:111–121 · doi:10.1111/j.1365-2125.1975.tb01566.x
  129. Nightingale CH, Greene DS, Quintiliani R (1975) Pharmacokinetics and clinical use of cephalosporin antibiotics. J Pharm Sci 64:1899–1927 · doi:10.1002/jps.2600641202
  130. Nordström L, Ringbert H, Cronberg S, Tjernström O, Walder M (1990) Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 25:159–173 · DOI
  131. Norrby SR (1987) Side effects of cephalosporins. Drugs 34:105–120 · DOI
  132. Owens RC Jr, Ambrose PG (2005) Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41:S144–S157 · DOI · Paper page
  133. Pai MP, Cottrell ML, Kashuba AD, Bertino JS (2014) Pharmacokinetics and pharmacodynamics of anti-infective agents, Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Elsevier, Amsterdam
  134. Pestka S (1971) Inhibitors of ribosome functions. Annu Rev Microbiol 25:487–562 · DOI · Paper page
  135. Pillai S, Eliopoulos G, Moellering R (2010) Principles of anti-infective therapy. Principles and practice of infectious diseases, 7th edn. Churchill Livingston Elsevier, Philadelphia, PA, pp 267–278
  136. Piscitelli S, Danziger L, Rodvold K (1992) Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 11:137–152
  137. Pittinger C, Adamson R (1972) Antibiotic blockade of neuromuscular function. Annu Rev Pharmacol 12:169–184 · doi:10.1146/annurev.pa.12.040172.001125
  138. Pouretedal HR (2014) Preparation and characterization of azithromycin nanodrug using solvent/antisolvent method. Int Nano Lett 4:103 · doi:10.1007/s40089-014-0103-x
  139. Price EJ, Venables PJ (1995) Drug-induced lupus. Drug Saf 12:283–290 · doi:10.2165/00002018-199512040-00008
  140. Radwanski E, Batra V, Cayen M, Korduba C, Cutler D, Affrime M, Nomeir A, Lin C (1997) Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections. Antimicrob Agents Chemother 41:1794–1796 · doi:10.1128/aac.41.8.1794
  141. Rando RR (2001) Aminoglycoside binding to human and bacterial A-site rRNA decoding region constructs. Bioorg Med Chem 9:2601–2608 · DOI
  142. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM (2004) Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351:1089–1096 · DOI · Paper page
  143. Resistant BLPM (2007) Saponins from Eugenia jambolana with antibacterial activity against beta-lactamase producing methicillin resistant Staphylococcus aureus. Res J Med Pianti 1:1–6
  144. Rich ML, Ritterhoff RJ, Hoffmann RJ (1950) A fatal case of aplastic anemia following chloramphenicol (chloromycetin) therapy. Ann Intern Med 33:1459–1467 · doi:10.7326/0003-4819-33-6-1459
  145. Romano A, Torres M, Namour F, Mayorga C, Artesani M, Venuti A, Guéant J, Blanca M (2002) Immediate hypersensitivity to cephalosporins. Allergy 57:52–57 · DOI
  146. Ruoff JW, Sams R (1985) Pharmacokinetics and bioavailability of cephalothin in horse mares. Am J Vet Res 46:2085–2090
  147. Saivin S, Houin G (1988) Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15:355–366 · DOI · Paper page
  148. Sams R, Ruoff JW (1985) Pharmacokinetics and bioavailability of cefazolin in horses. Am J Vet Res 46:348–352
  149. Sandoval RM, Reilly JP, Running W, Campos SB, Santos JR, Phillips CL, Molitoris BA (2006) A non-nephrotoxic gentamicin congener that retains antimicrobial efficacy. J Am Soc Nephrol 17:2697–2705 · doi:10.1681/asn.2005101124
  150. SanFilippo JA (1976) Infantile hypertrophic pyloric stenosis related to ingestion of erythromycine estolate: a report of five cases. J Pediatr Surg 11:177–180 · DOI
  151. Sanwikarja S, Kauffmann R, Serlie J (1989) Tubulointerstitial nephritis associated with pyrazinamide. Neth J Med 34:40–46
  152. Sawant KK, Patel MH, Patel K (2016) Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro–in vivo evaluations. Drug Dev Ind Pharm 42:758–768 · doi:10.3109/03639045.2015.1104344
  153. Schentag JJ, Ballow CH (1991) Tissue-directed pharmacokinetics. Am J Med 91:S5–S11 · DOI · Paper page
  154. Schultz JC, Adamson JS Jr, Workman WW, Norman TD (1963) Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 269:999–1004 · DOI · Paper page
  155. Segal JL, Brunnemann SR, Gray DR (1988) Gentamicin bioavailability and single-dose pharmacokinetics in spinal cord injury. Drug Intell Clin Pharm 22:461–465 · doi:10.1177/106002808802200603
  156. Shaffer D, Singer S, Korvick J, Honig P (2002) Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration adverse event reporting system. Clin Infect Dis 35:197–200 · DOI
  157. Sharma A, Kumar Arya D, Dua M, Chhatwal GS, Johri AK (2012) Nano-technology for targeted drug delivery to combat antibiotic resistance. Taylor & Francis, London · DOI
  158. Sharma M, Gupta N, Gupta S (2016) Implications of designing clarithromycin loaded solid lipid nanoparticles on their pharmacokinetics, antibacterial activity and safety. RSC Adv 6:76621–76631 · DOI
  159. Shearer M, Bechtold H, Andrassy K, Koderisch J, McCarthy P, Trenk D, Jähnchen E, Ritz E (1988) Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 28:88–95 · doi:10.1002/j.1552-4604.1988.tb03106.x
  160. Shils ME (1963) Renal disease and the metabolic effects of tetracycline. Ann Intern Med 58:389–408 · doi:10.7326/0003-4819-58-3-389
  161. Shively ML, Thompson DC (1995) Oral bioavailability of vancomycin solid-state emulsions. Int J Pharm 117:119–122 · doi:10.1016/0378-5173(94)00331-x
  162. Shyu W, Shah V, Campbell D, Wilber R, Pittman K, Barbhaiya R (1992) Oral absolute bioavailability and intravenous dose-proportionality of Cefprozil in humans. J Clin Pharmacol 32:798–803 · doi:10.1002/j.1552-4604.1992.tb03885.x
  163. Siddiqui K, Waris A, Akber H, Munir K, Mir M, Khan MW, Aman W (2017) Physicochemical modifications and Nano particulate strategies for improved bioavailability of poorly water soluble drugs. Pharmaceut Nanotechnol 5:276–284
  164. Signs S, Tan J, Salstrom S, File T (1992) Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. Antimicrob Agents Chemother 36:1400–1403 · doi:10.1128/aac.36.7.1400
  165. Singh M, Varshneya C, Telang R, Srivastava A (2005) Alteration of pharmacokinetics of oxytetracycline following oral administration of Piper longum in hens. J Vet Sci 6:197–200 · doi:10.4142/jvs.2005.6.3.197
  166. Smith K, Leyden JJ (2005) Safety of doxycycline and minocycline: a systematic review. Clin Ther 27:1329–1342 · DOI · Paper page
  167. Smith CL, Powell K (2000) Review of the sulfonamides and trimethoprim. Pediatr Rev 21:368–371 · doi:10.1542/pir.21-11-368
  168. Smith AL, Weber A (1983) Pharmacology of chloramphenicol. Pediatr Clin N Am 30:209–236 · doi:10.1016/s0031-3955(16)34330-9
  169. Somogyi AA, Bochner F, Hetzel D, Williams DB (1995) Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin. Pharm Res 12:149–154 · DOI
  170. Sörgel F, Kinzig M (1993) Pharmacokinetics of gyrase inhibitors, part 1: basic chemistry and gastrointestinal disposition. Am J Med 94:44S–55S · DOI
  171. Spyker DA, Rugloski RJ, Vann RL, O’Brien WM (1977) Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrob Agents Chemother 11:132–141 · DOI
  172. Staib AH, Beermann D, Harder S, Fuhr U, Liermann D (1989) Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule). Am J Med 87:S66–S69 · DOI
  173. Suarez CR, Ow EP (1992) Chloramphenicol toxicity associated with severe cardiac dysfunction. Pediatr Cardiol 13:48–51 · doi:10.1007/bf00788231
  174. Suber RL, Lee C, Torosian G, Edds GT (1981) Pharmacokinetics of sulfisoxazole compared in humans and two monogastric animal species. J Pharm Sci 70:981–984 · doi:10.1002/jps.2600700903
  175. Sutherland JM (1959) Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J Dis Child 97:761–767
  176. Swabb EA, Sugerman A, Stern M (1983) Oral bioavailability of the monobactam aztreonam (SQ 26,776) in healthy subjects. Antimicrob Agents Chemother 23:548–550 · doi:10.1128/aac.23.4.548
  177. Swartz MN (1997) Use of antimicrobial agents and drug resistance. N Engl J Med 337(7):491–492 · DOI · Paper page
  178. Sykes R, Bonner D (1985) Discovery and development of the monobactams. Rev Infect Dis 7:S579–S593 · doi:10.1093/clinids/7.supplement_4.s579
  179. Tod M, Padoin C, Petitjean O (2000) Clinical pharmacokinetics and pharmacodynamics of isepamicin. Clin Pharmacokinet 38:205–223 · DOI
  180. Tomé AM, Filipe A (2011) Quinolones. Drug Saf 34:465–488 · DOI
  181. Turner M, Aziz SR (2002) Management of the pregnant oral and maxillofacial surgery patient. J Oral Maxillofac Surg 60:1479–1488 · doi:10.1053/joms.2002.36132
  182. Uppal R, Verma S, Verma V, Garg S (1997) Comparative pharmacokinetics of amikacin following a single intramuscular or subcutaneous administration in goats (Capra hircus). Vet Res 28:565–570
  183. Van Bambeke F, Barcia-Macay M, Lemaire S, Tulkens PM (2006) Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr Opin Drug Discov Develop 9:218
  184. Verbist L, Tjandramaga T, Mullie A, Van Hecken A, Verbesselt R, De Schepper P (1982) Comparative study of in vitro antimicrobial activity and human pharmacokinetics of Dibekacin and tobramycin. Acta Clin Belg 37:148–157 · doi:10.1080/22953337.1982.11718857
  185. Vial T, Biour M, Descotes J, Trepo C (1997) Antibiotic-associated hepatitis: update from 1990. Ann Pharmacother 31:204–220 · DOI
  186. Vogelman B, Craig WA (1986) Kinetics of antimicrobial activity. J Pediatr 108:835–840 · DOI · Paper page
  187. Von Drygalski A, Curtis BR, Bougie DW, McFarland JG, Ahl S, Limbu I, Baker KR, Aster RH (2007) Vancomycin-induced immune thrombocytopenia. N Engl J Med 356:904–910 · DOI · Paper page
  188. Wallace RJ Jr, Brown BA, Griffith DE (1993) Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 16:215–221 · DOI
  189. Weber WW, Hein DW (1979) Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 4:401–422 · DOI · Paper page
  190. Werner JC, Whitman V, Schuler HG, Fripp RR, Rannels AM, Kasales CJ, LaNoue KF (1985) Acute myocardial effects of chloramphenicol in newborn pigs: a possible insight into the gray baby syndrome. J Infect Dis 152:344–350 · DOI
  191. Williams PE, Harding SM (1984) The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J Antimicrob Chemother 13:191–196 · DOI
  192. Winckler K (1981) Tetracycline ulcers of the oesophagus. Endoscopy, histology and roentgenology in two cases, and review of the literature. Endoscopy 13:225–228 · doi:10.1055/s-2007-1021691
  193. Wise EM, Park JT (1965) Penicillin: its basic site of action as an inhibitor of a peptide cross-linking reaction in cell wall mucopeptide synthesis. Proc Natl Acad Sci 54:75–81 · DOI · Paper page
  194. Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau J-C, Bagot M (1995) Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 131:544–551 · doi:10.1001/archderm.1995.01690170046006
  195. Wood M, Farrell W, Kattan S, Williams J (1975) Activity of minocycline and tetracycline against respiratory pathogens related to blood levels. J Antimicrob Chemother 1:323–331 · doi:10.1093/jac/1.3.323
  196. Woolf D (1965) Chloramphenicol blindness. BMJ Publishing Group, London
  197. Xie J, Talaska AE, Schacht J (2011) New developments in aminoglycoside therapy and ototoxicity. Hear Res 281:28–37 · DOI · Paper page
  198. Yates AB (2008) Management of patients with a history of allergy to beta-lactam antibiotics. Am J Med 121:572–576 · DOI
  199. Yunis A (1973) Chloramphenicol induced bone marrow suppression, Seminars in hematology. WB Saunders Ltd, Philadelphia, pp 225–234
  200. Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA (2001) Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 21:1037–1045 · doi:10.1592/phco.21.13.1037.34625

200 of 201 shown

Metadata

Authors
Ullah, I., Ali, E., & Fakhar-ud-Din
Venue
Emerging Contaminants and Associated Treatment Technologies
Published
2020
Pages
211-238
ISSN
  • 2524-6402
  • 2524-6410
Cited by
9
References
0
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bioavailability of Antibiotics and Their Toxicity. https://app.cochat.ai/papers/10.1007/978-3-030-40422-2_10
The paper
Ullah, I., Ali, E., & Fakhar-ud-Din. (2020). Bioavailability of Antibiotics and Their Toxicity. Emerging Contaminants and Associated Treatment Technologies. https://doi.org/10.1007/978-3-030-40422-2_10

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.